<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163249">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02066896</url>
  </required_header>
  <id_info>
    <org_study_id>LLLXS</org_study_id>
    <nct_id>NCT02066896</nct_id>
  </id_info>
  <brief_title>Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome</brief_title>
  <official_title>Low Level Laser Therapy For The Treatment Of Xerostomia In Primary Sjogren`s Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to test the efficacy and safety of low laser therapy to treat  the
      xerostomia of patients with primary Sjogren's Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Sjogren's Syndrome is a disease that affects around 0,5% of the population and is mainly
      characterized for inflammatory involvement of salivary and lacrimal glands.

      The xerostomia leads to low quality of life caused by dry sensations that can disturb the
      taste, the speaking, the swallow and chewing functions in the affected patients. The absent
      saliva can cause increase of dental caries and decays.

      Until now, there is no effective treatment that  increases the amount of saliva and the
      patients  have low improvements with cholinergic drugs such as pilocarpine and cevimeline.
      These drugs can cause unpleasant collateral effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The xerostomia inventory</measure>
    <time_frame>up to fourth week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The questionary has 11 questions with graduations 1-5 each question according to the severity of dryness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>salivary  analysis by proteomic</measure>
    <time_frame>up to fourth week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Saliva samples will be submitted to chromatography analysis and dual absorptiometry in order to analyse the protein profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary flux measurement</measure>
    <time_frame>up to fourth week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The salivary flux will be measured at the same time,  without previous meal or tooth brushing, drinking or eating, in a quiet room, spilled saliva in a collector tube graduated in mm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>KERATOCONJUNCTIVITIS SICCA</condition>
  <condition>XEROSTOMIA</condition>
  <condition>SICCA SYNDROME</condition>
  <condition>PRIMARY SJOGREN SYNDROME</condition>
  <arm_group>
    <arm_group_label>Sham Laser therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12 sessions of sham laser therapy (no active intervention)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 sessions of laser therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser 3R 790nm infrared Ga AIAs</intervention_name>
    <description>The laser beam applied bilaterally in noncontact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland/ Equipment in a turn-off mode Laser therapy</description>
    <arm_group_label>Laser therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser 3R 790 nm infrared  GaAIAs</intervention_name>
    <description>The laser beam applied bilaterally in noncontact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland. Equipment in a turn-on mode
Laser therapy</description>
    <arm_group_label>Laser therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with primary Sjogren Syndrome according criteria american european 2002.

          -  Salivary flux non stimulated &lt; 0,1 ml/min.

        Exclusion Criteria:

          -  hepatitis B and/or C

          -  radiotherapy in the glandular area (previous)

          -  other connective diseases

          -  thyroidopathy non compensated

          -  GVHD graft-versus-host disease

          -  HIV

          -  Sarcoidosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia M Trevisani, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tania A Fidelix, investigator</last_name>
    <phone>55 11 991346992</phone>
    <email>tsafidelix@uol.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tania S A Fidelix</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04602-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tania SA Fidelix, Dr</last_name>
      <phone>55 11 41255840</phone>
      <email>tsafidelix@uol.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>August 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>TANIA SALES DE ALENCAR FIDELIX</investigator_full_name>
    <investigator_title>DR.</investigator_title>
  </responsible_party>
  <keyword>Sjogrens Syndrome</keyword>
  <keyword>Syndrome, Sjogren's</keyword>
  <keyword>Sjogren Syndrome</keyword>
  <keyword>Sicca Syndrome</keyword>
  <keyword>Syndrome, Sicca</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Xerostomia</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
